<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="71627">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02173275</url>
  </required_header>
  <id_info>
    <org_study_id>1309014313</org_study_id>
    <secondary_id>R01HL118019</secondary_id>
    <nct_id>NCT02173275</nct_id>
  </id_info>
  <brief_title>Computed TomogRaphic Evaluation of Atherosclerotic DEtermiNants of Myocardial IsChEmia</brief_title>
  <acronym>CREDENCE</acronym>
  <official_title>Computed TomogRaphic Evaluation of Atherosclerotic DEtermiNants of Myocardial IsChEmia (The CREDENCE Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study seeks to determine the accuracy of using anatomic and physiologic information
      measurable by computed tomography features of stenosis, plaque, fractional flow reserve-CT
      and to compare this measure to stress testing for the detection of myocardial ischemia
      against the gold standard of cardiac catheterization with fractional flow reserve. The
      hypothesis of this proposal is that integrating anatomic plaque features with physiologic
      fractional flow reserve-CT will optimize identification of coronary lesions that are
      ischemia-causing by computed tomography .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CREDENCE trial will be a prospective multicenter cross-sectional study of 618
      individuals (n=309 [derivation cohort]; n=309 [validation cohort]) who will undergo stress
      test, computed tomography, cardiac catheterization and fractional flow reserve. For the
      purposes of the study, either stress test or computed tomography will have been performed
      for clinical purposes, with the other test being performed as part of trial procedure. Study
      analyses will focus on the diagnostic performance of the information derived by stress test
      versus computed tomography against an invasive gold standard of cardiac catheterization and
      fractional flow reserve for an endpoint of vessel territory-specific ischemia. In keeping
      with prior studies, vessel territories will be comprised of the left anterior descending
      artery (and diagonal branches), the left circumflex artery (and obtuse marginal branches)
      and the right coronary artery (and posterolateral branch and posterior descending artery).

      To date, the relative performance of traditional stress imaging testing compared to the
      entirety of information proffered by CT has not been assessed compared to an unbiased gold
      standard. The study proposed herein will directly address this unmet need.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic accuracy of vessel territory-specific ischemia of an integrated stenosis-APC-FFRCT measure by CT</measure>
    <time_frame>48-60 months</time_frame>
    <description>The primary endpoint is the diagnostic accuracy of an integrated stenosis-APC-FFRCT metric by CT, as compared to perfusion or perfusion-MBF stress imaging testing for vessel territory-specific ischemia as determined by FFR (gold standard).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Individual comparisons of APCs or FFRCT to MPI vessel-specific perfusion deficits or reduced MBF.</measure>
    <time_frame>48-60 months</time_frame>
    <description>To compare the accuracy of the individual components of APCs or FFRCT to MPI vessel-specific perfusion deficits or reduced MBF against ischemia by FFR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-PCI FFR prediction by FFRCT &quot;virtual stenting&quot;</measure>
    <time_frame>48-60 months</time_frame>
    <description>To determine the accuracy of FFRCT &quot;virtual stenting&quot; to post-PCI FFR value of &gt;0.80 and determine the correlation between the FFRCT &quot;virtual stenting&quot; to post-PCI FFR.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">618</enrollment>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>derivation cohort</arm_group_label>
    <description>n = 309</description>
  </arm_group>
  <arm_group>
    <arm_group_label>validation cohort</arm_group_label>
    <description>n = 309</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive consenting adult patients who meet all of the inclusion criteria and none of
        the exclusion criteria will be asked to participate in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;18 years

          2. Scheduled to undergo clinically-indicated non-emergent invasive coronary angiography

        Exclusion Criteria:

          1. Known CAD (myocardial infarction [MI], percutaneous coronary interventions [PCIs],
             coronary artery bypass graft [CABG],)

          2. Hemodynamic instability

          3. Inability to provide written informed consent

          4. Concomitant participation in another clinical trial in which subject is subject to
             investigational drug or device

          5. Pregnant state

          6. Absolute contraindication to iodinated contrast due to prior near-fatal anaphylactoid
             reaction (laryngospasm, bronchospasm, cardiorespiratory collapse, or equivalent)

          7. Serum creatinine ≥1.7 mg/dl or Glomerular Filtration Rate &lt;30 ml/min

          8. Baseline irregular heart rhythm (e.g., atrial fibrillation, etc.)

          9. Heart rate ≥100 beats per minute

         10. Systolic blood pressure ≤90 mm Hg

         11. Contraindications to β blockers or nitroglycerin or adenosine

         12. BMI &gt;40 kg/m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James K Min, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Quynh A Truong, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James K Min, MD</last_name>
    <phone>6469626258</phone>
    <email>jkm2001@med.cornell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Quynh A Truong, MD MPH</last_name>
    <phone>6469626267</phone>
    <email>qat9001@med.cornell.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Heart Center Research, LLC</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Ridner, MD</last_name>
      <phone>256-539-4080</phone>
      <email>mridner@theheartcenter.md</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mobile Cardiology Associates</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Cole</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Hospital</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Jang</last_name>
      <phone>408-972-3410</phone>
      <email>James.J.Jang@kp.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oconee Heart and Vascular Center at St Mary's Hospital</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erick Avelar, MD</last_name>
      <phone>706-389-3440</phone>
      <email>eavelar@gru.edu]</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wiliam Beaumont Hospital</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>St. Luke's Lipid and Diabetes Research Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Randall Thompson, MD</last_name>
      <phone>913-269-8676</phone>
      <email>rthompson@saint-lukes.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renown Heart and Vascular</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Rowan, MD</last_name>
      <email>cessna7391@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>U. Joseph Schoepf, MD</last_name>
      <phone>843-876-7146</phone>
      <email>schoepf@musc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faisal Nabi, MD</last_name>
      <phone>713-441-3625</phone>
      <email>fnabi@houstonmethodist.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiac Center of Texas</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akram Khan, MD</last_name>
      <phone>972-562-2345</phone>
      <email>arhum2000@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multicare HS Institute for Research &amp; Innovation</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98372</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinay Malhotra, MD</last_name>
      <phone>253-572-7320</phone>
      <email>Vinay.Malhotra@multicare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Health Care- St. Paul's Hospital; University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Leipsic</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bin Lu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino, IRCCS and University of Milan</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniele Andreini, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Toscana Gabriele Monasterio</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessia Gimelli, MD</last_name>
      <phone>+39 050 315 2216</phone>
      <email>Gimelli@ftgm.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryo Nakazato</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Cardiovascular Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyuk-Jae Chang</last_name>
    </contact>
    <investigator>
      <last_name>Hyuk-Jae Chang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paul Stradins University Hospital</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrejs Erglis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>China</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 11, 2017</lastchanged_date>
  <firstreceived_date>June 23, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
